Impact of vancomycin area under the curve in early or later phase on efficacy and nephrotoxicity in patients with enterococcal bloodstream infections: a multicenter study.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Vancomycin*/therapeutic use ; Vancomycin*/pharmacokinetics ; Vancomycin*/blood ; Anti-Bacterial Agents*/therapeutic use ; Anti-Bacterial Agents*/pharmacokinetics ; Anti-Bacterial Agents*/blood ; Gram-Positive Bacterial Infections*/drug therapy ; Gram-Positive Bacterial Infections*/mortality ; Gram-Positive Bacterial Infections*/blood ; Gram-Positive Bacterial Infections*/microbiology ; Bacteremia*/drug therapy ; Bacteremia*/microbiology ; Area Under Curve*; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Acute Kidney Injury/chemically induced ; Thailand ; Enterococcus/drug effects ; Treatment Outcome ; Adult ; Aged, 80 and over

Background: The optimal pharmacokinetic and pharmacodynamic (PK/PD) parameters of vancomycin that can improve outcomes in enterococcal infections remain controversial. To clarify the therapeutic target for this antibiotic, this study aimed to determine vancomycin PK/PD parameters associated with efficacy in the early (during 72 h) or later (after 72 h) phase of treatment and nephrotoxicity in enterococcal bloodstream infection patients.
Methods: This multicenter retrospective study reviewed medical records of patients with enterococcal bloodstream infections treated with intravenous vancomycin infusion for at least 72 h between January 2016 and March 2024 at Phramongkutklao Hospital or Nopparatrajathanee Hospital in Bangkok, and Rachaburi Hospital in Rachaburi Province, Thailand. Patients with data available on serum vancomycin concentration were analyzed. The primary outcomes were 30-day mortality and acute kidney injury. The estimates of the mean 24-h area under the curve in the first 72 h (AUC 24 ) and in steady state (AUC ss ) were determined by Bayesian theorem.
Results: Overall, 201 vancomycin concentrations were measured within the first 72 h after vancomycin treatment, while 156 were in a steady state (> 72 h). According to Classification and Regression Tree analysis, vancomycin AUC at 420 mg·h/l was the PK/PD target for 30-day mortality. Results reveal that patients with AUC 24 (early phase) and AUC ss  < 420 mg·h/l (later phase) had significantly higher 14-day, 30-day, and in-hospital mortality than AUC ≥ 420 mg·h/l groups. In addition, patients with AUC 24  ≥ 420 mg·h/l in the early phase had significantly reduced microbiological failure (p = 0.004). Patients with AUC ≥ 700 mg·h/l in early and later phases had significantly increased acute kidney injury risk. In addition, patients receiving concomitant nephrotoxic drugs had an AUC cutoff value of 650 mg·h/l. Multivariate Cox regression analysis showed that vancomycin AUC ss  < 420 mg·h/l, unknown source of bacteremia, and acute kidney injury were significantly associated with 30-day mortality.
Conclusions: AUC 420-650 mg·h/l in early and later phases was the target of vancomycin's PK/PD in enterococcal bacteremia patients for efficacy and to prevent acute kidney injury. This study suggests close monitoring of vancomycin levels to ensure efficacy and safety.
Competing Interests: Declarations. Ethics approval and consent to participate: The study was approved by the Institutional Review Board of the Royal Thai Army Medical Department at Phramongkutklao College of Medicine and Phramongkutklao Hospital (approval number Q001h/66), Human Research Ethics Committee of Ratchaburi Hospital (approval number RBHEC005/66), and Human Research Ethics Committee of Nopparatrajathanee Hospital (approval number 14/2566). Data were collected after ethics approval and with permission from the hospital director. Competing interests: The authors declare no competing interests.
(© 2025. The Author(s).)

JAMA. 2005 Aug 17;294(7):813-8. (PMID: 16106006)
BMC Infect Dis. 2021 Oct 26;21(1):1099. (PMID: 34702193)
Pharmaceutics. 2021 Aug 31;13(9):. (PMID: 34575453)
Surg Gynecol Obstet. 1985 Jun;160(6):557-61. (PMID: 4002111)
Antimicrob Agents Chemother. 1988 Jun;32(6):848-52. (PMID: 3415206)
J Glob Antimicrob Resist. 2021 Mar;24:198-204. (PMID: 33359937)
Am J Health Syst Pharm. 2020 May 19;77(11):835-864. (PMID: 32191793)
Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):639-652. (PMID: 30919233)
Clin Infect Dis. 2014 Sep 1;59(5):666-75. (PMID: 24867791)
Pharmacotherapy. 2018 Dec;38(12):1174-1183. (PMID: 30362592)
Br J Clin Pharmacol. 2019 Jun;85(6):1215-1226. (PMID: 30768726)
Clin Pharmacol Ther. 2017 Sep;102(3):459-469. (PMID: 28474732)
Clin Microbiol Infect. 2011 Jul;17(7):1078-83. (PMID: 20946408)
Clin Ther. 2007 Jun;29(6):1107-15. (PMID: 17692725)
Antibiotics (Basel). 2020 Oct 04;9(10):. (PMID: 33020463)
Antibiotics (Basel). 2021 Jan 22;10(2):. (PMID: 33499102)
BMC Infect Dis. 2006 Sep 26;6:145. (PMID: 17002792)
Antibiotics (Basel). 2021 Jan 11;10(1):. (PMID: 33440660)
Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. (PMID: 21576448)
PLoS One. 2019 May 14;14(5):e0216801. (PMID: 31086400)
Antibiotics (Basel). 2021 Jun 14;10(6):. (PMID: 34198646)
Antimicrob Resist Infect Control. 2020 Jan 31;9(1):22. (PMID: 32005223)
Front Pharmacol. 2022 Jan 28;12:773994. (PMID: 35153743)
Clin Infect Dis. 2019 Nov 13;69(11):1881-1887. (PMID: 30715208)
Antimicrob Resist Infect Control. 2017 Jul 4;6:73. (PMID: 28680588)
Clin Microbiol Infect. 2013 Apr;19(4):E181-9. (PMID: 23398607)
Antimicrob Agents Chemother. 2017 Apr 24;61(5):. (PMID: 28242672)
Nephron Clin Pract. 2012;120(4):c179-84. (PMID: 22890468)
Antimicrob Agents Chemother. 2018 Feb 23;62(3):. (PMID: 29263057)
J Pharm Health Care Sci. 2019 May 16;5:8. (PMID: 31093330)
Drugs. 2017 Jul;77(11):1143-1154. (PMID: 28573434)

Keywords: Acute kidney injury; Enterococci; Glycopeptide; PK/PD target; Therapeutic drug monitoring

6Q205EH1VU (Vancomycin)
0 (Anti-Bacterial Agents)

Date Created: 20250128 Date Completed: 20250129 Latest Revision: 20250131

20250131

PMC11773776

10.1186/s12879-024-10399-9

39875832